VIVELLE Drug Patent Profile

When do Vivelle patents expire, and what generic alternatives are available?

Vivelle is a drug marketed by Sandoz and is included in two NDAs.

The generic ingredient in VIVELLE is estradiol. There are seventy-five drug master file entries for this compound. Forty-eight suppliers are listed for this compound. Additional details are available on the estradiol profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Vivelle

A generic version of VIVELLE was approved as estradiol by BARR LABS INC on October 22^nd, 1997.

Summary for VIVELLE

US Patents:	0
Applicants:	1
NDAs:	2
Raw Ingredient (Bulk) Api Vendors:	1
Clinical Trials:	4
Patent Applications:	4,144
Drug Prices:	Drug price information for VIVELLE
Drug Sales Revenues:	Drug sales revenues for VIVELLE
DailyMed Link:	VIVELLE at DailyMed

See drug prices for VIVELLE

Recent Clinical Trials for VIVELLE

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)	Early Phase 1
University of Virginia	Early Phase 1
Genentech, Inc.	Phase 4

See all VIVELLE clinical trials

US Patents and Regulatory Information for VIVELLE

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Sandoz	VIVELLE	estradiol	SYSTEM;TRANSDERMAL	020323-005	Aug 16, 2000		DISCN	No	No
Sandoz	VIVELLE-DOT	estradiol	SYSTEM;TRANSDERMAL	020538-005	Jan 8, 1999	AB1	RX	Yes	No
Sandoz	VIVELLE	estradiol	SYSTEM;TRANSDERMAL	020323-003	Oct 28, 1994		DISCN	No	No
Sandoz	VIVELLE-DOT	estradiol	SYSTEM;TRANSDERMAL	020538-006	Jan 8, 1999	AB1	RX	Yes	No
Sandoz	VIVELLE	estradiol	SYSTEM;TRANSDERMAL	020323-001	Oct 28, 1994		DISCN	No	No

Expired US Patents for VIVELLE

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Sandoz	VIVELLE	estradiol	SYSTEM;TRANSDERMAL	020323-001	Oct 28, 1994
Sandoz	VIVELLE	estradiol	SYSTEM;TRANSDERMAL	020323-002	Oct 28, 1994
Sandoz	VIVELLE	estradiol	SYSTEM;TRANSDERMAL	020323-003	Oct 28, 1994
Sandoz	VIVELLE	estradiol	SYSTEM;TRANSDERMAL	020323-002	Oct 28, 1994
Sandoz	VIVELLE	estradiol	SYSTEM;TRANSDERMAL	020323-004	Oct 28, 1994

International Patents for VIVELLE

See the table below for patents covering VIVELLE around the world.

Country	Patent Number	Title	Estimated Expiration
Norway	307363
Australia	622776
Norway	962833
Australia	606840
Canada	2109099	METHODE ET DISPOSITIF DE FABRICATION D'UN DISPOSITIF D'ADMINISTRATION TRANSDERMIQUE DE MEDICAMENTS (METHOD AND APPARATUS FOR FORMING A TRANSDERMAL DRUG DEVICE)

Supplementary Protection Certificates for VIVELLE

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
0771217	07C0001	France		PRODUCT NAME: ETHINYLESTRADIOL BETADEX CLATHRATE; NAT. REGISTRATION NO/DATE: NL 32343 20060710; FIRST REGISTRATION: NL - RVG 31781 20050804
0771217	CA 2006 00038	Denmark		PRODUCT NAME: ETHINYLESTRADIOL (SOM BETA-CYCLODEXTRIN-CLATHRAT) OG DROSPIRENON; NAT. REG. NO/DATE: 38687 20060627; FIRST REG. NO/DATE: EU RVG 31781 20050804
0402407	97C0005	Belgium		PRODUCT NAME: ESTRADIOL HEMIHYDRAAT; NAT. REGISTRATION NO/DATE: 298 IS 190 F 15 19960806; FIRST REGISTRATION: GB PL/0053/0241 19950711
2782584	C202130068	Spain		PRODUCT NAME: COMPOSICION QUE CONTIENE ESTRADIOL (17BETA-ESTRADIOL), INCLUYENDO EN FORMA DE HEMIHIDRATO, Y PROGESTERONA; NATIONAL AUTHORISATION NUMBER: 85988-NL/H/4994/001/DC; DATE OF AUTHORISATION: 20210528; NUMBER OF FIRST AUTHORISATION IN EUROPEAN ECONOMIC AREA (EEA): BE582231; DATE OF FIRST AUTHORISATION IN EEA: 20210406
0770388	09C0018	France		PRODUCT NAME: ESTRADIOL VALERATE; DIENOGEST; NAT. REGISTRATION NO/DATE: NL35170 20081210; FIRST REGISTRATION: BE327792 20081103

Market Dynamics and Financial Trajectory for the Pharmaceutical Drug: VIVELLE

Last updated: July 31, 2025

---

Introduction

VIVELLE, a synthetic hormone-based oral contraceptive, plays a prominent role within the global reproductive health market. As a product with substantial clinical adoption and market penetration, understanding the dynamics that influence its market trajectory is crucial for stakeholders — including pharmaceutical companies, investors, healthcare providers, and policymakers.

This analysis explores the evolving market landscape, competitive positioning, regulatory environment, and financial prospects of VIVELLE, providing a comprehensive overview of its current and future potential.

---

Market Overview and Positioning

VIVELLE’s core composition includes ethinylestradiol and desogestrel, positioning it within the third-generation oral contraceptive segment. The global contraceptive market, valued at approximately USD 22 billion in 2021, is projected to grow at a CAGR of 6-7% over the next five years, driven by increasing awareness, expanding healthcare access, and a rise in the prevalence of reproductive health needs.[1]

VIVELLE’s competitive advantage stems from its established efficacy, safety profile, and consumer trust. It is approved in multiple markets including North America, Europe, and parts of Asia, fostering steady revenue streams and potential for regional expansion, especially into emerging markets with growing contraceptive needs.

---

Market Dynamics

1. Demographic Shifts and Consumer Trends

The global demographic landscape influences VIVELLE’s market prospects. With the world's female population aged 15-49 reaching over 1 billion, and a rising urban middle class seeking reliable contraception options, demand is significant. Additionally, increasing acceptance of hormonal contraceptives, coupled with shifting attitudes towards family planning, magnifies VIVELLE's relevance.

2. Regulatory Environment

Regulatory approvals shape VIVELLE's market access. The European Medicines Agency (EMA) and the U.S. Food and Drug Administration (FDA) maintain rigorous standards to ensure safety and efficacy. Recent regulatory trends emphasize long-term safety data and minimization of adverse effects, influencing formulation refinements and labeling.

Regulatory bodies are also increasingly scrutinizing safety profiles concerning cardiovascular risks and hormonal impacts. Positive safety assessments facilitate market retention, but any adverse safety concerns could hinder sales or delay approvals, impacting the financial trajectory.

3. Competitive Landscape

VIVELLE faces competition from both branded and generic oral contraceptives. Major players like Bayer, Janssen, and Teva dominate, offering diverse formulations. The entry of low-cost generics, especially in emerging markets, exerts pricing pressure on branded products like VIVELLE.

Nonetheless, VIVELLE’s differentiation relies on its favorable side effect profile and clinician or consumer preference, which can sustain premium positioning. Strategic marketing and sustained clinical evidence are critical amid fierce competition.

4. Innovation and Formulation Developments

The ongoing pipeline includes extended-cycle formulations and lower-dose variants, aligning with consumer preferences for convenience and reduced side effects. Technological advances exploring non-hormonal options or combination therapies could threaten VIVELLE's market share if alternative therapies demonstrate superior safety or efficacy.

Simultaneously, digital health integration and personalized contraceptive options are redefining the landscape, urging pharmaceutical innovators to adapt product offerings.

---

Financial Trajectory and Revenue Outlook

1. Revenue Growth Trends

VIVELLE’s sales have shown consistent growth due to robust demand in mature markets and expanding access in emerging regions. However, growth rates are moderated by patent expirations, generic competition, and regulatory pressures.

Globally, the contraceptive segment is expected to reach USD 29 billion by 2026, with VIVELLE projected to capture a significant share due to its established brand presence. Assuming an average annual growth rate of approximately 4-6%, revenues could approach USD 1-2 billion within five years, contingent on market expansion and competitive dynamics.

2. Pricing Strategies and Market Penetration

Pricing remains a critical lever. Premium pricing sustains margins in developed markets but may impede uptake in price-sensitive regions. Introductory strategies like tiered pricing, local manufacturing, and partnerships could enhance penetration.

Licensing and geographic expansion, especially into Asia-Pacific and Latin America, will serve as catalysts for revenue growth, aligning with demographic trends and unmet needs.

3. Cost Structure and Profitability

Manufacturing costs are moderated through economies of scale and supply chain efficiencies. R&D expenses are primarily tied to formulation improvements and safety studies. Regulatory compliance incurs ongoing costs, but these are offset by patent protections or exclusivity periods, enhancing profitability.

Post-patent expiry, generic competition could diminish profit margins unless differentiated formulations or associated products sustain premium pricing.

4. Risks and Opportunities

Key risks include regulatory delays, safety concerns, patent challenges, and competitive pricing pressures. Conversely, opportunities lie in developing next-generation formulations, expanding into newer markets, and leveraging digital health collaborations to enhance adherence and market loyalty.

---

Regulatory and Market Challenges

Unforeseen regulatory setbacks can delay market entry or extend approval timelines, impacting revenue forecasts. Safety concerns, particularly cardiovascular risks associated with hormonal contraceptives, remain areas of active monitoring, influencing labeling updates and consumer confidence.

Furthermore, changing sociopolitical climates and healthcare policies, such as contraceptive access mandates or restrictions, can either facilitate or impede market growth.

---

Conclusion

VIVELLE's market dynamics are shaped by demographic trends, regulatory frameworks, competitive forces, and innovation trajectories. While robust market demand and established brand recognition underpin its financial outlook, intense competition and evolving regulatory landscapes necessitate strategic agility.

The future of VIVELLE hinges on continued product efficacy, safety improvements, geographic expansion, and adaptation to emerging health technologies. Stakeholders should closely monitor clinical developments, market entry strategies, and regulatory changes to optimize investments and operational planning.

---

Key Takeaways

• Sustainable Growth Requires Innovation: Developing next-generation formulations that address safety and convenience can differentiate VIVELLE in a crowded market.
• Regulatory Vigilance is Crucial: Ensuring compliance and proactively addressing safety concerns will safeguard market access and reputation.
• Market Expansion is Key: Emerging markets offer significant growth potential, especially with tailored pricing and distribution strategies.
• Strategic Partnerships Matter: Collaborations with local healthcare providers and digital health platforms can enhance market penetration and adherence.
• Monitoring Competitive Landscape: Keeping abreast of generic entrants and alternative contraceptive options will inform pricing and marketing strategies.

---

FAQs

1. How does VIVELLE compare to other oral contraceptives in safety and efficacy?
VIVELLE is comparable to other third-generation contraceptives regarding efficacy. Its safety profile is well-established, with ongoing monitoring for cardiovascular and hormonal side effects, aligning with industry standards.

2. What are the primary factors influencing VIVELLE’s market share growth?
Key factors include demographic demand, regulatory approvals, innovative formulation development, and strategic market expansion into emerging regions.

3. How might regulatory changes impact VIVELLE’s future sales?
Stricter safety assessments or new regulatory restrictions could delay approvals or necessitate reformulations, potentially reducing sales. Conversely, favorable policy environments could accelerate market penetration.

4. What are the main competitive threats to VIVELLE?
Generic versions, alternative contraceptive methods like IUDs or implants, and emerging non-hormonal options pose competitive challenges.

5. What strategies can pharmaceutical companies adopt to maximize VIVELLE’s market potential?
Investing in clinical research, expanding into underserved markets, leveraging digital health tools, and differentiating through safety and convenience can enhance market share.

---

Sources
[1] Grand View Research, “Contraceptive Drugs Market Size, Share & Trends Analysis Report,” 2022.